Carfilzomib,lenalidomide and dexamethasone (KRd) as induction therapy in high-risk newly diagnosed multiple myeloma Meeting Abstract
| Authors: | Tan, C.; Korde, N.; Derkach, A.; Hultcrantz, M.; Maclachlan, K. H.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; Lesokhin, A.; Lahoud, O. B.; Shah, G. L.; Scordo, M.; Chung, D.; Landau, H.; Giralt, S. A.; Hofmeister, C. C.; Kaufman, J. L.; Nooka, A. K.; Usmani, S. Z.; Lonial, S.; Joseph, N. S. |
| Abstract Title: | Carfilzomib,lenalidomide and dexamethasone (KRd) as induction therapy in high-risk newly diagnosed multiple myeloma |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 1996 |
| Language: | English |
| ACCESSION: | WOS:001159306707222 |
| DOI: | 10.1182/blood-2023-190279 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
